September 8, 2021 Webinar - Blood Product Selection Post-BMT

Wednesday, September 8, 2021 / 3:00 PM - 4:00 PM EDT

Title: Blood Product Selection for Transfusion of Bone Marrow Transplant Patients

Speaker: 

Ljiljana Vasovic, MD
Associate Director of Cellular Therapy & Assistant Director of Transfusion Medicine
New York Presbyterian Hospital-Weill Cornell Campus
Chief of Clinical Pathology and Transfusion Medicine
New York-Presbyterian/Lower Manhattan Hospital

Bio: Dr. Vasovic is Chief of Clinical Pathology and Transfusion Medicine at New York-Presbyterian/Lower Manhattan, Associate Medical Director of the Cellular Therapy Laboratory at New York-Presbyterian Hospital, and is Assistant Professor of Pathology and Laboratory Medicine, Weill Cornell Medicine.  Dr. Vasovic received a Medical Degree from the University of Belgrade, School of Medicine.  She completed an immunology research fellowship at Memorial Sloan Kettering Cancer Center, a residency in Pathology at Lenox Hill Hospital, New York University, a Hematopathology fellowship at Albert Einstein College of Medicine and Transfusion Medicine Fellowship at Harvard Medical School, Joint Program in Transfusion Medicine.  Dr. Vasovic's primary research interests include optimizing stem cell transplants procedures for the treatment of hematologic malignancies and enhancing quality assurance programs for cellular therapy laboratories.

Abstract: Appropriate therapeutic and supportive transfusion management of ABO, as well as non-ABO, blood group incompatible Hematopoietic progenitor cell transplantation (HPCT) recipients, can become a critical and challenging task during the post-transplantation time period.  20% to 50% of HPCT are ABO incompatible.  Hemolysis is a cardinal symptom of blood group incompatibility.  Immediate hemolysis is predominantly due to a high titer of anti-ABO isohemagglutinins.  Delayed hemolysis in major incompatible transplants presents as delayed erythroid engraftment or pure red cell aplasia.  Delayed hemolysis in minor incompatible transplants usually presents as transient hemolysis due to an expansion of passenger lymphocytes.  Transfusion of blood components compatible with both the donor and recipient should be considered.  Blood product selection will be discussed supported by case presentations.

Objectives:

1. Review major and minor ABO Incompatible hematopoietic progenitor cell transplantation (HPCT).
2. Discuss passenger lymphocyte syndrome.
3. Review transfusion support for ABO-incompatible HPCT transplant recipient.

Pricing:

• Member: $20 per session & $55 entire series
• Non-Member: $45 per session & $130 entire series
• Institution: $75 per session & $200 entire series

To receive member pricing, be sure to sign in.